Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Total 13F shares
-
40,123,971
-
Share change
-
+3,042,713
-
Total reported value
-
$575,784,532
-
Put/Call ratio
-
39%
-
Price per share
-
$14.35
-
Number of holders
-
105
-
Value change
-
+$26,148,562
-
Number of buys
-
72
-
Number of sells
-
43
Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q2 2017
As of 30 Jun 2017,
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) was held by
105 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,123,971 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, Kohlberg Kravis Roberts & Co. L.P., BlackRock Inc., VANGUARD GROUP INC, Partner Fund Management, L.P., STATE STREET CORP, JPMORGAN CHASE & CO, UBS ASSET MANAGEMENT AMERICAS INC, and ORBIMED ADVISORS LLC.
This page lists
105
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.